Adjuvant therapeutic potential of tonabersat in the standard treatment of glioblastoma: A preclinical F98 glioblastoma rat model study

PURPOSE: Even with an optimal treatment protocol, the median survival of glioblastoma (GB) patients is only 12–15 months. Hence, there is need for novel effective therapies that improve survival outcomes. Recent evidence suggests an important role for connexin (Cx) proteins (especially Cx43) in the...

Descripción completa

Detalles Bibliográficos
Autores principales: De Meulenaere, Valerie, Bonte, Ellen, Verhoeven, Jeroen, Kalala Okito, Jean-Pierre, Pieters, Leen, Vral, Anne, De Wever, Olivier, Leybaert, Luc, Goethals, Ingeborg, Vanhove, Christian, Descamps, Benedicte, Deblaere, Karel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6802836/
https://www.ncbi.nlm.nih.gov/pubmed/31634381
http://dx.doi.org/10.1371/journal.pone.0224130

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6802836/
https://www.ncbi.nlm.nih.gov/pubmed/31634381
http://dx.doi.org/10.1371/journal.pone.0224130

Ejemplares similares